Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
WILMINGTON, Del., Jan. 15, 2016 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of Vital Therapies, Inc. (NASDAQ:VTL)?
- Did you purchase your shares between April 17, 2014 and August 21, 2015, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of Vital Therapies, Inc. (“Vital Therapies” or the “Company”) (NASDAQ:VTL) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the Southern District of California on behalf of all persons or entities that purchased the common stock of Vital Therapies between April 17, 2014 and August 21, 2015, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you wish to serve as lead plaintiff, you must move the Court no later than February 1, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased shares of Vital Therapies during the Class Period, or purchased shares prior to the Class Period and still hold Vital Therapies, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/vital-therapies-inc-vtl.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
